Tag:
Biocon
Latest Headlines
Latest Headlines
Biocon hiring 300 scientists for new R&D complex in India
India's Biocon cut the ribbon on a new biologics R&D complex that will host a multi-disciplinary group of more than 300 scientists developing a new generation of "affordable" biologics.
Novo seen to benefit from Pfizer-Biocon split
Pfizer ( $PFE ) and Biocon's decision to dissolve their partnership was bad news for the Indian company's stock, but Novo Nordisk ( $NVO ) got a boost.
UPDATED:Pfizer's marketing pact with Biocon falls apart
Pfizer ( $PFE ) and Biocon have gone their separate ways. The two companies had planned to jointly market Biocon's biosimilar diabetes drugs, but now they've chosen to go it alone. Pfizer will pursue an independent diabetes strategy, while Biocon will seek new marketing partners to take its products to other emerging markets, the U.S. and Europe.
Pfizer walks away from $350M insulin pact with India's Biocon
In a move widely viewed as a bad blow to India's biggest biotech, Pfizer ( $PFE ) has written off its $200 million upfront payment to India's Biocon ( $BIOCON )--right along with all the licensing rights involved in their biosimilar insulin development deal.
Pfizer amps up R&D partnering activity in China and India
A day after Pfizer ( $PFE ) inked a deal with a joint venture partner in China to develop new generic drugs, the pharma giant is spreading the word that it's in the hunt for local drug development...
Biocon seeking rich partner for insulin pill development
Diabetes patients currently inject their insulin, of course. But India's Biocon sees opportunity in developing an oral insulin pill, despite a late-stage clinical trial setback this year for its
Biocon chief vows near-term pact on oral insulin
The high-profile CEO of India's Biocon says that she's closing in on a big-name pharma partner for the company's oral insulin program. Kiran Mazumdar-Shaw told Reuters that "we are in advanced
Biocon chief outlines go-go biotech expansion plan, chides regulators
The chairperson of India's Biocon, the always outspoken Kiran Mazumdar-Shaw, has outlined some new steps aimed at keeping the biotech's growth rate roaring along at breakneck speed. She told
Can Biocon get a $1B pharma deal for its oral insulin program?
India's Economic Times is reporting that Biocon is negotiating a blockbuster partnership deal on its oral insulin program. And the newspaper is tossing around some eye-popping upfront numbers cited
India's biotech leaders criticize lack of R&D support
The budget plans newly outlined by India's finance minister has drawn some harsh criticism form the biotech industry's top leaders. "Even baby diapers got more attention from the FM," Bharat
